Press Room
15 March 2007
La Merie and PharmaPlus team up to provide No-Frills business intelligence solutions
New downloadable and searchable financial deal database PharmaPlus Financials provides extracts to evaluate and analyze licensing deals over the last ten years at affordable prices
Read more8 March 2007
Weight management is not enough for cannabinoid type 1 (CB1) receptor antagonists to become a commercial success
Huge clinical development program of first-in-class CB1 antagonist rimonabant to show benefits beyond weight reduction and avoid image as life-style drug
Read more1 March 2007
The new class of dipeptidyl peptidase IV (DPP-IV) inhibitors has one clear leader and many followers
Merck & Co clearly leads the field of DPP-IV inhibitors which has many followers in clinical development. The first companies already abandoned the field.
Read more26 February 2007
TOP Classes of Biologics with 2006 Sales of US$ 63.8 bln
Sales of the major cancer antibodies grew by 57 % to US$ 10.6 bln in 2006. Cancer antibodies are challenging the still no. 1 selling class of erythropoietins with 2006 sales of US$ 11.9 bln, but the lowest growth rate…
Read more14 February 2007
The market of recombinant coagulation factors is growing with next generation products
The growing market of recombinant coagulation factors posted 2006 sales of more than US$ 4.6 bln. The four market leaders compete with a staggered series of next generation products and face competition by new entrants into the various segments of…
Read more5 February 2007
Dosing convenience is mandatory to keep pace in the pipeline race of GLP-1 analogs for type 2 diabetes
The emerging market of GLP-1 analogs with 2006 sales of US$ 430.2 mln in the first full market year of twice-daily exenatide attracts other players in the diabetes field, but urges them to top exenatide by more convenient products
Read more2 February 2007
Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26
A free compilation of the 2006 sales of the TOP 20 blockbuster and other major recombinant antibodies and proteins will be provided by La Merie Business Intelligence starting February 26
Read more11 January 2007
The right balance drives the field of PPAR agonist R&D
A strongly growing market of now more than US$ 6 bln in 2006 for only tow PPAR gamma agonists founds the basis for a heavily researched field of next generation mono, dual or triple PPAR agonists with fine-tuned subtype combinations…
Read moreFeatured Reports
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
RElated News